Search results
Earnings call: Lumos Pharma gears up for Phase 3 trial of LUM-201 By Investing.com
Investing.com· 5 hours agoThe company has completed a constructive End-of-Phase 2 Meeting with the FDA and is planning to...
Acurx gears up for Phase 3 trials of CDI antibiotic candidate By Investing.com
Investing.com· 11 hours agoFollowing a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), the...
89bio begins Phase III trial of treatment for steatohepatitis with cirrhosis
Clinical Trials Arena via Yahoo Finance· 18 hours agoUS-based biopharmaceutical company 89bio has begun the Phase III ENLIGHTEN-Cirrhosis clinical trial of pegozafermin ...
Q1 2024 Acurx Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 37 minutes agoIn January, we announced positive comparative microbiology and microbiome data for ibezapolstat, our lead antibiotic candidate in C. diff patients from the Phase IIb
Verrica and Torii to conduct global wart treatment trial By Investing.com
Investing.com· 10 hours ago(NASDAQ: NASDAQ:VRCA), in collaboration with Japan's Torii Pharmaceutical Co. Ltd., has announced an...
Replicate Bioscience Presents Positive Data from Phase 1 Trial and Preclinical Data with Novel...
FOX21 Colorado Springs· 5 days ago"At ASGCT, Replicate is presenting two important breakthroughs in srRNA...
Recce Pharmaceuticals doses first participants in next cohort Phase I/II UTI/Urosepsis rapid...
Proactive Investors· 23 hours agoRecce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has dosed the first participants in the next cohort ...
Ractigen Therapeutics Receives IND Approval from China's NMPA to Initiate Phase 1 Clinical Trials...
FOX 23 News Albany· 15 hours agoThe IND-opening study is a Phase I, randomized, double-blind, placebo-controlled study evaluating...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for...
WTNH-TV New Haven· 14 hours agoOrally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE. Self-administered PUR3100 showed ...
Candel Lights Up Investors' Portfolio With 830% Gain
RTT News· 2 hours agoShares of Candel Therapeutics Inc. (CADL) have gained more than 830% in the past 2 months, thanks to the substantial progress achieved across its clinical programs.
